Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Non-therapeutic Feasibility Study to Evaluate the Kinetics and Test-retest Repeatability and Reproducibility of the Radioligand [11C]-UCB-J for Imaging Synaptic Density in Healthy Subjects and Mild-to-moderate Alzheimer's Disease Subjects

Next Previous
Search
Trial Profile

A Non-therapeutic Feasibility Study to Evaluate the Kinetics and Test-retest Repeatability and Reproducibility of the Radioligand [11C]-UCB-J for Imaging Synaptic Density in Healthy Subjects and Mild-to-moderate Alzheimer's Disease Subjects

Status: Completed
Phase of Trial: Phase 0

Latest Information Update: 08 Apr 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Carbon 11 UCB J (Primary)
  • Indications Alzheimer's disease
  • Focus Pharmacokinetics
  • Sponsors Alkermes; Rodin Therapeutics

    • Most Recent Events

    • 09 Sep 2019 Status changed from recruiting to completed.
    • 25 Jun 2019 According to a Rodin Therapeutics media release,data from this study will be presented at the upcoming Alzheimer's Association International Conference (AAIC) meeting in Los Angeles on July 14-18.
    • 25 Mar 2019 Planned End Date changed from 20 Mar 2019 to 20 May 2019.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top